Results from the Odyssey trial will be presented at this year’s Conference on Retroviruses and Opportunistic Infections in Boston, USA.

ODYSSEY has reached a major milestone by completing the recruitment of participants to the main trial. A big thank you to all the sites and everyone else for their hard work and continuous effort put into making the study a success.

We are pleased to report that a presentation from the ODYSSEY team at MRC CTU at UCL was well received at the 40th Annual Conference of the International Society for Clinical Biostatistics in Leuven, Belgium (14 – 18 July 2019). Rebecca Turner delivered the talk as part of the Bayesian clinical trials session on Tuesday morning (16 July).

We are delighted to report that a late breaker oral presentation on the key PK substudy nested within the ODYSSEY trial was accepted and presented at the 10th IAS Conference on HIV Science (IAS 2019) on 21-24 July, 2019.

Adult doses of an antiviral drug could offer a practical and accessible option for children weighing 20-25kg living with HIV. The results of the pharmacokinetic sub-study (measuring levels of drug in the blood to check if doses are correct), part of the ODYSSEY trial, were presented at the Conference on Retroviruses and Opportunistic Infections, in Seattle, Washington.

ODYSSEY B, which compares dolutegravir versus standard-of-care drugs in HIV-infected children who are starting second-line treatment, has completed recruitment ahead of target. 395 children have enrolled, mostly in Africa. Enrollment into ODYSSEY A for children starting treatment for the first time continues.

With more than 350 patients randomized into the trial, ODYSSEY has reached 50% of its recruitment target. Congratulations to the ODYSSEY team!

We are happy to announce that the first patient was enrolled in the ODYSSEY study by the team in Zimbabwe. We encourage all the sites to follow.